STOCK TITAN

Ardent Health holders close 8M-share sale at $14.50

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Ardent Health, Inc. (ARDT) reported that EGI-AM Investments, L.L.C. and ALH Holdings, LLC completed a resale offering of 8,000,000 common shares at a public offering price of $14.50 per share. Ardent Health received no proceeds from the stockholders’ sales. The underwriters received a 30-day option to purchase up to 1,200,000 additional shares at the public offering price, less underwriting discounts and commissions.

On November 19, 2026, Ardent Health repurchased 1,500,000 shares from the underwriters at a repurchase price of $13.7025 per share, using existing cash on hand. The purchase was outside the company’s previously disclosed repurchase program and did not reduce the approximately $48.0 million remaining authorization.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Shares sold 8,000,000 shares Selling stockholders’ offering, which closed November 19, 2026
Public offering price $14.50 per share Selling stockholders’ offering
Underwriters’ option Up to 1,200,000 shares 30-day option to purchase additional shares
Option period 30 days Underwriters’ option
Shares repurchased 1,500,000 shares Ardent Health repurchase on November 19, 2026
Repurchase price $13.7025 per share Shares repurchased from the underwriters
Remaining repurchase authorization Approximately $48.0 million Authorization was not reduced by the concurrent share repurchase
Concurrent Share Repurchase financial
"the “Concurrent Share Repurchase”"
A concurrent share repurchase is when a company buys back its own shares at the same time it conducts another equity-related transaction, such as a new stock issuance or a selling shareholder offering. It matters to investors because the simultaneous buyback can offset dilution, change the number of shares outstanding and ownership percentages, and influence per-share metrics like earnings per share, much like swapping items in and out of a basket to keep the overall quantity or composition steady.
shelf registration statement regulatory
"pursuant to a shelf registration statement on Form S-3"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
underwriting discounts and commissions financial
"less the underwriting discounts and commissions"
Underwriting discounts and commissions are fees paid to financial institutions that help sell new securities to investors. They act like a commission for their role in connecting companies with buyers, often reducing the amount of money the issuing company raises. For investors, understanding these costs helps gauge how much of their investment is going toward the actual securities versus fees paid to middlemen.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ARDT shares did the selling stockholders sell, and at what price?

EGI-AM Investments, L.L.C. and ALH Holdings, LLC sold 8,000,000 common shares at $14.50 per share. The offering closed on November 19, 2026, and Ardent Health received no proceeds from the stockholders’ sale.

How many shares did Ardent Health repurchase in the offering?

Ardent Health repurchased 1,500,000 shares at $13.7025 per share from the underwriters on November 19, 2026. The company used existing cash on hand, and the purchase did not reduce the approximately $48.0 million remaining under its previously disclosed repurchase authorization.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001756655 0001756655 2026-11-17 2026-11-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): November 17, 2026

 

 

 

ARDENT HEALTH, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware 001-42180 61-1764793

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

 

340 Seven Springs Way, Suite 100, Brentwood, Tennessee 37027
(Address of Principal Executive Offices) (Zip Code)

  

(615) 296-3000

(Registrant’s Telephone Number, including Area Code)

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Class  

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.01 par value per share   ARDT   New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

Item 8.01. Other Events.

 

On November 17, 2026, Ardent Health, Inc. (the “Company”), EGI-AM Investments, L.L.C. (“EGI-AM”), an affiliated entity of Equity Group Investments, and ALH Holdings, LLC (a subsidiary of Ventas, Inc.) (together with EGI-AM, the “Selling Stockholders”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC and Barclays Capital Inc., as representatives of the several underwriters named in Schedule 1 thereto (collectively, the “Underwriters”), for the sale by the Selling Stockholders of 8,000,000 shares of common stock, par value $0.01 per share, of the Company (the “Common Stock”), at a price to the public of $14.50 per share (the “Offering”). The Offering closed on November 19, 2026. The Company did not receive any proceeds from the sale of shares of Common Stock by the Selling Stockholders in the Offering.

 

In connection with the Offering, the Selling Stockholders have granted the Underwriters a 30-day option to purchase up to an additional 1,200,000 shares of Common Stock at the public offering price, less the underwriting discounts and commissions.

 

Also pursuant to the Underwriting Agreement, on November 19, 2026, the Company repurchased from the Underwriters 1,500,000 shares of Common Stock sold by the Selling Stockholders in the Offering, at a purchase price equal to $13.7025 per share, which is the price at which the Underwriters purchased the shares of Common Stock from the Selling Stockholders (the “Concurrent Share Repurchase”). The Company used existing cash on hand to fund the Concurrent Share Repurchase. The Underwriters did not receive any compensation for the shares repurchased by the Company. The Concurrent Share Repurchase was not made pursuant to the Company’s previously disclosed stock repurchase program and does not reduce the approximately $48.0 million of remaining repurchase authorization thereunder.

 

The Offering was made pursuant to a shelf registration statement on Form S-3 (File No. 333-289763) filed with the Securities and Exchange Commission (the “SEC”) on August 21, 2025, and which was declared effective on August 25, 2025 (the “Registration Statement”), a prospectus, dated August 25, 2025 included as part of the Registration Statement, a preliminary prospectus supplement, dated November 17, 2026 and filed with the SEC on November 17, 2026, and a final prospectus supplement, dated November 17, 2026 and filed with the SEC on November 18, 2026. The Underwriting Agreement contains certain customary representations, warranties and agreements by the Company and the Selling Stockholders, conditions to closing, indemnification rights and obligations of the parties and termination rights. The foregoing description of the terms in the Underwriting Agreement is qualified in its entirety by reference to the Underwriting Agreement, which is attached hereto as Exhibit 1.1 and incorporated herein by reference.

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit No. Description
   
1.1 Underwriting Agreement, dated as of November 17, 2026, by and among Ardent Health, Inc., certain stockholders named therein and J.P. Morgan Securities LLC and Barclays Capital Inc., as representatives of the several underwriters named in Schedule 1 thereto.
   
104 Cover Page Interactive Data File (embedded within the inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 19, 2026 ARDENT HEALTH, INC.
     
  By: /s/ Stephen C. Petrovich
  Name: Stephen C. Petrovich
  Title: Executive Vice President & General Counsel

 

 

 

Filing Exhibits & Attachments

4 documents

Keep reading